Table 2.
Adverse events.
| Adverse Effects |
Prevalence of Adverse Events [95% CIs] (%) |
Number of Studies Analysed |
Total Number of Patients | Heterogeneity | OR [95% CIs] | p-Value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|---|---|
| I 2 | p-Value | I 2 | p-Value | ||||||
| Dizziness | 21.7 [11.4–31.9] | 7 | 883 | 93% | <0.0001 | 1.9 [1.4–2.5] * | <0.0001 | 0% | 0.42 |
| Nausea | 17.0 [4.7–29.3] | 4 | 212 | 87% | <0.0001 | 1.0 [0.2–3.7] | 0.88 | 81% | 0.001 |
| Vomiting | 5.2 [0.0–12.3] | 3 | 192 | 84% | 0.003 | 0.3 [0.0–4.5] | 0.40 | 88% | 0.004 |
| Agitation | 2.0 [0.0–4.3] | 2 | 140 | 0% | 0.63 | 2.1 [0.3–16.8] | 0.47 | 0% | 0.43 |
| Difficulty concentrating |
58.3 [38.6–78.1] | 1 | 24 | NA | NA | 5.3 [1.5–19.0] | 0.01 | NA | NA |
| Confusion | 50 [30.0–70.0] | 1 | 24 | NA | NA | 7.0 [1.6–29.9] | 0.009 | NA | NA |
| Emergence phenomenon |
30.0 [9.9–50.1] | 1 | 20 | NA | NA | 18.4 [1.0–352.6] | 0.05 | NA | NA |
| Dry mouth | 25.0 [7.7–42.3] | 1 | 24 | NA | NA | 0.09 [0.02–0.3] | 0.0004 | NA | NA |
| Fatigue | 14.7 [6.7–22.7] | 1 | 75 | NA | NA | 0.9 [0.4–2.0] | 0.71 | NA | NA |
| Disorientation | 7.8 [5.6–10.0] | 1 | 552 | NA | NA | 9.2 [3.6–23.4] | <0.00001 | NA | NA |
| Drowsiness | 10.7 [3.7–17.7] | 1 | 75 | NA | NA | 3.0 [0.8–11.6] | 0.12 | NA | NA |
| Euphoria | 10.7 [3.7–17.7] | 1 | 75 | NA | NA | 0.5 [0.2–1.4] | 0.19 | NA | NA |
| Headache | 4.6 [0.0–9.7] | 1 | 65 | NA | NA | 3.1 [0.3–30.6] | 0.33 | NA | NA |
| Hypotension | 0.0 [0.0–6.5] | 1 | 20 | NA | NA | 0.04 [ 0.0–0.7] | 0.03 | NA | NA |
CIs: Confidence intervals; OR: Odds ratio, NA: Not applicable. * Six studies were considered in OR analysis.